• TRPV1 Somatosensory Control of Inflammation

  2026-09-16

  The 2025 iScience study shows that activating TRPV1-positive sensory nerves at the nape suppresses systemic inflammation through coordinated brainstem, adrenal, vagal, sympathetic, and splenic pathways. Its combination of chemical stimulation, genetic validation, neuroendocrine measurements, and splenic RNA sequencing provides a mechanistic framework for studying somato-autonomic immune regulation.

• Tin Mesoporphyrin IX in HO Assays

  2026-09-15

  Tin Mesoporphyrin IX (chloride) enables controlled, competitive suppression of heme oxygenase for mechanistic assays spanning heme turnover, redox biology, and metabolic disease research. This guide connects a practical HO workflow with the reference study’s HO-1–ROS findings while clearly separating established evidence from proposed experimental extensions.

• Wortmannin: PI3K Inhibitor Workflow for HCC

  2026-09-15

  Wortmannin provides a practical pharmacological switch for testing how PI3K/AKT activity shapes ferroptosis resistance in hepatocellular carcinoma. This workflow connects pathway engagement, lipid peroxidation, viability, and protein biomarkers while addressing solubility, exposure, and off-target interpretation.

• Pcbp1, Mitochondria, and B Cell Immunity

  2026-09-14

  The reference study identifies the RNA-binding protein Pcbp1 as a posttranscriptional regulator of mitochondrial integrity in B cells. By linking Pcbp1–Fdxr regulation to complex I activity, mitochondrial reactive oxygen species, translation, IgM production, and germinal center responses, the work provides a mechanistic framework for studying how metabolism supports humoral immunity.

• TAK-715: A Selective p38 MAPK Inhibitor Workflow

  2026-09-14

  TAK-715 combines nanomolar p38α inhibition with a practical workflow for cytokine, stress-response, and rheumatoid arthritis research. Its value is greatest when pathway suppression is paired with phospho-protein, cytokine, and dephosphorylation readouts rather than relying on a single endpoint.

• Methylprednisolone Workflows for Bone Models

  2026-09-13

  Methylprednisolone gives researchers a controllable glucocorticoid challenge that connects anti-inflammatory signaling with osteoclast-driven bone damage. This guide translates macrophage, PBMC, skin, and rat osteonecrosis workflows into practical assay design, preparation, and troubleshooting decisions.

• TCEP Hydrochloride for Protein and Assay Workflows

  2026-09-12

  TCEP hydrochloride combines odorless, water-compatible disulfide reduction with practical utility in protein preparation, structural analysis, redox assays, and assay-development screening. This guide translates the capture-and-release LFA concept into actionable workflows while distinguishing validated findings from optimization starting points.

• Drug Response Metrics in Cancer: Schwartz Dissertation

  2026-09-11

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug responses. The framework supports more precise interpretation of in vitro cancer pharmacology by considering response magnitude, composition, and timing rather than relying on a single viability endpoint.

• Tofacitinib: A Systems View of RA Macrophages

  2026-09-11

  Tofacitinib and CP-690550 are examined as mechanistic probes of rheumatoid arthritis macrophage dysfunction, not merely as JAK inhibitors. This article connects cytokine signaling blockade with mitochondrial readouts and provides an assay framework for distinguishing direct pathway effects from broader immune reprogramming.

• EZ Cap EGFP mRNA 5-moUTP Workflow Guide

  2026-09-10

  Build reproducible reporter assays with Cap1-capped, 5-methoxyuridine-modified EGFP mRNA and an optimized poly(A) tail. This practical guide connects transfection quality control, translation efficiency testing, innate-immune monitoring, and in vivo fluorescence workflows.

• Perospirone Inhibits Coronary Vascular Kv Channels

  2026-09-10

  A 2025 Journal of Applied Toxicology study identifies a previously unrecognized, concentration-dependent inhibition of voltage-gated K+ currents by perospirone in freshly isolated rabbit coronary arterial smooth muscle cells. The pharmacological profile implicates Kv1.5 channels and provides a mechanistic basis for evaluating vascular ion-channel effects alongside the compound’s established serotonergic and dopaminergic actions.

• MK-8745: Reading Aurora A Dependency

  2026-09-09

  MK-8745 is a potent, selective Aurora A inhibitor for dissecting mitotic failure, p53-contextual apoptosis, and tumor dependency. This article translates retinoblastoma evidence into a practical framework for choosing assays and interpreting cell-cycle, apoptosis, and xenograft results.

• GI 254023X: ADAM10 Inhibition Workflows

  2026-09-09

  GI 254023X is a selective ADAM10 inhibitor for connecting sheddase activity with Notch1 signaling, leukemic-cell phenotypes, and endothelial barrier protection. This practical guide combines dose planning, orthogonal readouts, comparative interpretation, and troubleshooting for translational cell and vascular models.

• SAR131675: VEGFR-3 Inhibitor Workflows

  2026-09-08

  Build reproducible VEGFR-3 target-engagement, lymphangiogenesis, angiogenesis, and hepatic fibrosis assays with SAR131675. This workflow emphasizes fresh compound handling, orthogonal controls, and the VEGFC–VEGFR-3 axis revealed in a recent NASH fibrosis study.

• Protease Inhibitor Cocktail EDTA-Free Guide

  2026-09-08

  Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) helps limit endogenous proteolysis during protein extraction and sample preparation while avoiding EDTA-related effects on divalent-cation-sensitive workflows. It is suitable for lysates, Western blotting, co-immunoprecipitation, and phosphorylation-related assays, but it should not replace cold handling, rapid processing, or assay-specific compatibility testing.

8109 records 1/541 page Next 12345 下5页 Last page